Investors & Media : on Data Provided by Refinitiv. Minimum 15 minutes delayed. Intra 3 mo. 6 mo. 1 yr. News Releases Intercept Pharmaceuticals to Participate in Piper Sandler’s 34th Annual Healthcare Conference on December 1, 2022 Nov 22, 2022 Intercept Announces Development Program for Next-Generation FXR Agonist INT-787 in Severe Alcohol-Associated Hepatitis Nov 07, 2022 Intercept Announces Additional Positive Data in Fibrosis due to NASH from New Analysis of Phase 3 REGENERATE Study at AASLD The Liver Meeting® 2022 Nov 07, 2022 Intercept Announces Two Analyses Demonstrating Improvement in Outcomes, Including Transplant-Free Survival, for PBC Patients Treated with OCA to be Presented at AASLD The Liver Meeting® 2022 Nov 06, 2022 View all press releases > Recent Events and Presentations Piper Sandler’s 34th Annual Healthcare Conference Dec 1, 2022 Q3 2022 Intercept Pharmaceuticals Earnings Call Nov 1, 2022 at 8:30 AM EDT H.C. Wainwright’s 6th Annual NASH Investor Conference Oct 17, 2022 at 2:30 PM EDT Baird Global Healthcare Conference Sep 14, 2022 at 9:05 AM EDT View all events & presentations >
Intercept Pharmaceuticals to Participate in Piper Sandler’s 34th Annual Healthcare Conference on December 1, 2022 Nov 22, 2022
Intercept Announces Development Program for Next-Generation FXR Agonist INT-787 in Severe Alcohol-Associated Hepatitis Nov 07, 2022
Intercept Announces Additional Positive Data in Fibrosis due to NASH from New Analysis of Phase 3 REGENERATE Study at AASLD The Liver Meeting® 2022 Nov 07, 2022
Intercept Announces Two Analyses Demonstrating Improvement in Outcomes, Including Transplant-Free Survival, for PBC Patients Treated with OCA to be Presented at AASLD The Liver Meeting® 2022 Nov 06, 2022
